美国 · SEC FORM 4
Evolus, Inc.
EOLS · Nasdaq · CIK 0001570562 · Healthcare · Drug Manufacturers—Specialty & Generic
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
1 同一窗口内观察到的 Form 4 交易行
1 sales · 0 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-08-15 · Stewart Brady.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 5,628,168
- 上期报告
- 5,530,759
- 日均成交量
- 603,494
- 回补天数
- 9.3
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-08-15 | Stewart Brady | 买入 (P) | Common Stock | 30,000 | USD 6.82 | USD 204,600 | SEC 申报 ↗ |
| 2025-06-09 | White Albert G III | 买入 (P) | Common Stock | 20,000 | USD 9.45 | USD 189,000 | SEC 申报 ↗ |
| 2023-08-15 | Malik Vikram | 买入 (P) | Common Stock | 174,967 | USD 7.41 | USD 1,296,505 | SEC 申报 ↗ |
| 2022-09-12 | HAYMAN ROBERT | 买入 (P) | Common Stock | 1,091 | USD 10.78 | USD 11,761 | SEC 申报 ↗ |
| 2022-09-09 | HAYMAN ROBERT | 买入 (P) | Common Stock | 8,909 | USD 10.35 | USD 92,208 | SEC 申报 ↗ |
| 2022-09-07 | HAYMAN ROBERT | 买入 (P) | Common Stock | 5,000 | USD 10.05 | USD 50,250 | SEC 申报 ↗ |
| 2022-09-07 | HAYMAN ROBERT | 买入 (P) | Common Stock | 4,967 | USD 10.05 | USD 49,918 | SEC 申报 ↗ |
| 2022-09-06 | BLANK SIMONE | 买入 (P) | Common Stock | 20,000 | USD 9.24 | USD 184,800 | SEC 申报 ↗ |
| 2022-09-06 | FARRELL PETER C | 买入 (P) | Common Stock | 10,000 | USD 9.10 | USD 91,000 | SEC 申报 ↗ |
| 2021-08-27 | Medytox Inc. | 买入 (P) | Common Stock, $0.00001 par value per share | 51,000 | USD 10.93 | USD 557,430 | SEC 申报 ↗ |
| 2021-08-26 | Medytox Inc. | 买入 (P) | Common Stock, $0.00001 par value per share | 66,000 | USD 11.02 | USD 727,320 | SEC 申报 ↗ |
| 2021-08-25 | Medytox Inc. | 买入 (P) | Common Stock, $0.00001 par value per share | 44,000 | USD 11.12 | USD 489,280 | SEC 申报 ↗ |
| 2021-08-24 | Medytox Inc. | 买入 (P) | Common Stock, $0.00001 par value per share | 72,219 | USD 11.17 | USD 806,686 | SEC 申报 ↗ |
| 2021-08-23 | Medytox Inc. | 买入 (P) | Common Stock, $0.00001 par value per share | 69,781 | USD 11.03 | USD 769,684 | SEC 申报 ↗ |
| 2021-08-20 | Medytox Inc. | 买入 (P) | Common Stock, $0.00001 par value per share | 48,000 | USD 10.56 | USD 506,880 | SEC 申报 ↗ |
Form 4 申报证据
17 transaction lines in the latest 365-day window; 206 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-02 | MOATAZEDI DAVID | 卖出 (S) | Common Stock | 105,108 | USD 9.04 | USD 950,176 | SEC 申报 ↗ |
| 2026-03-20 | MOATAZEDI DAVID | 卖出 (S) | Common Stock | 13,669 | USD 4.75 | USD 64,928 | SEC 申报 ↗ |
| 2026-03-20 | Avelar Rui | 卖出 (S) | Common Stock | 3,119 | USD 4.75 | USD 14,815 | SEC 申报 ↗ |
展开近期 Form 4 证据 (17 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-02 | MOATAZEDI DAVID | 卖出 (S) | Common Stock | 105,108 | USD 9.04 | USD 950,176 | SEC 申报 ↗ |
| 2026-03-20 | MOATAZEDI DAVID | 卖出 (S) | Common Stock | 13,669 | USD 4.75 | USD 64,928 | SEC 申报 ↗ |
| 2026-03-20 | Avelar Rui | 卖出 (S) | Common Stock | 3,119 | USD 4.75 | USD 14,815 | SEC 申报 ↗ |
| 2026-03-17 | MOATAZEDI DAVID | 卖出 (S) | Common Stock | 116,720 | USD 4.89 | USD 570,761 | SEC 申报 ↗ |
| 2026-03-17 | Avelar Rui | 卖出 (S) | Common Stock | 29,996 | USD 4.89 | USD 146,680 | SEC 申报 ↗ |
| 2026-03-16 | MOATAZEDI DAVID | 期权行权／转换 (M) | Common Stock | 67,489 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-16 | Avelar Rui | 期权行权／转换 (M) | Common Stock | 8,804 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-17 | White Albert G III | 奖励／授予 (A) | Common Stock | 45,559 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-17 | Stewart Brady | 奖励／授予 (A) | Common Stock | 45,559 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-17 | Parschauer Karah Herdman | 奖励／授予 (A) | Common Stock | 45,559 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-17 | Mitchell Tatjana | 奖励／授予 (A) | Common Stock | 121,489 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-17 | Malik Vikram | 奖励／授予 (A) | Common Stock | 45,559 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-17 | MOATAZEDI DAVID | 奖励／授予 (A) | Common Stock | 313,212 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-17 | GILL DAVID N | 奖励／授予 (A) | Common Stock | 45,559 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-17 | Avelar Rui | 奖励／授予 (A) | Common Stock | 94,913 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-22 | MOATAZEDI DAVID | 卖出 (S) | Common Stock | 10,539 | USD 7.15 | USD 75,354 | SEC 申报 ↗ |
| 2025-12-22 | Avelar Rui | 卖出 (S) | Common Stock | 2,261 | USD 7.15 | USD 16,166 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | EOLS |
| CIK | 0001570562 |
| 行业 | Healthcare |
| 细分行业 | Drug Manufacturers—Specialty & Generic Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 206 transaction lines from 2020-01-07 to 2026-09-02 24 P purchase lines · 92 S sale lines · 90 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.